GlassScriptPhysician profile
Atul Aggarwal
NPI 1043290778
$14,938.75
in general payments reported to CMS, 2019-2025
41 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,836 · 2020: $849 · 2021: $1,251 · 2022: $1,594 · 2023: $1,645 · 2024: $1,172 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.80 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,989.36 | 2019-2025 | |
| Amgen INC. | $1,665.92 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $1,069.93 | 2021-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $785.79 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $761.16 | 2019-2023 | Farxiga |
| Shockwave Medical, INC | $528.14 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $475.16 | 2020-2023 | Impella |
| Medtronic, INC. | $386.67 | 2022-2025 | Corevalve Evolut R, Onyx 18, Onyx Frontier |
| Boston Scientific Corporation | $329.69 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $322.36 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Novartis Pharmaceuticals Corporation | $265.86 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $231.72 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $227.89 | 2021-2023 | Amplatzer Amulet |
| Irhythm Technologies, INC. | $214.04 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $171.45 | 2019-2024 | Xarelto |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.